Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × Random Allocation × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡